07:40 AM EDT, 04/11/2025 (MT Newswires) -- Verve Therapeutics ( VERV ) said Friday the US Food and Drug Administration granted fast track designation for its experimental VERVE-102 treatment for hyperlipidemia and high lifetime cardiovascular risk to lower low-density lipoprotein cholesterol.

The company is testing VERVE-102 in a phase 1b clinical trial. The study's demographic and initial safety and efficacy data are expected in Q2.

Verve Therapeutics ( VERV ) shares were up 4.9% in recent premarket activity.